Models

Dataset Information

0

Vazquez2014 - Chemical inhibition from amyloid protein aggregation kinetics


ABSTRACT: Vazquez2014 - Chemical inhibition from amyloid protein aggregation kinetics This model is described in the article: Modeling of chemical inhibition from amyloid protein aggregation kinetics. Vázquez JA. BMC Pharmacol Toxicol 2014; 15(1): 9 Abstract: BACKGROUNDS: The process of amyloid proteins aggregation causes several human neuropathologies. In some cases, e.g. fibrillar deposits of insulin, the problems are generated in the processes of production and purification of protein and in the pump devices or injectable preparations for diabetics. Experimental kinetics and adequate modelling of chemical inhibition from amyloid aggregation are of practical importance in order to study the viable processing, formulation and storage as well as to predict and optimize the best conditions to reduce the effect of protein nucleation. RESULTS: In this manuscript, experimental data of insulin, A?42 amyloid protein and apomyoglobin fibrillation from recent bibliography were selected to evaluate the capability of a bivariate sigmoid equation to model them. The mathematical functions (logistic combined with Weibull equation) were used in reparameterized form and the effect of inhibitor concentrations on kinetic parameters from logistic equation were perfectly defined and explained. The surfaces of data were accurately described by proposed model and the presented analysis characterized the inhibitory influence on the protein aggregation by several chemicals. Discrimination between true and apparent inhibitors was also confirmed by the bivariate equation. EGCG for insulin (working at pH?=?7.4/T?=?37°C) and taiwaniaflavone for A?42 were the compounds studied that shown the greatest inhibition capacity. CONCLUSIONS: An accurate, simple and effective model to investigate the inhibition of chemicals on amyloid protein aggregation has been developed. The equation could be useful for the clear quantification of inhibitor potential of chemicals and rigorous comparison among them. This model is hosted on BioModels Database and identified by: BIOMD0000000532. To cite BioModels Database, please use: BioModels Database: An enhanced, curated and annotated resource for published quantitative kinetic models. To the extent possible under law, all copyright and related or neighbouring rights to this encoded model have been dedicated to the public domain worldwide. Please refer to CC0 Public Domain Dedication for more information.

DISEASE(S): Alzheimer's Disease

SUBMITTER: Audald Lloret i Villas  

PROVIDER: BIOMD0000000532 | BioModels | 2014-07-30

REPOSITORIES: BioModels

altmetric image

Publications

Modeling of chemical inhibition from amyloid protein aggregation kinetics.

Vázquez José Antonio JA  

BMC pharmacology & toxicology 20140227


BACKGROUNDS: The process of amyloid proteins aggregation causes several human neuropathologies. In some cases, e.g. fibrillar deposits of insulin, the problems are generated in the processes of production and purification of protein and in the pump devices or injectable preparations for diabetics. Experimental kinetics and adequate modelling of chemical inhibition from amyloid aggregation are of practical importance in order to study the viable processing, formulation and storage as well as to p  ...[more]

Similar Datasets

2014-12-11 | BIOMD0000000561 | BioModels
2014-11-10 | BIOMD0000000555 | BioModels
2014-07-17 | BIOMD0000000531 | BioModels
2014-09-23 | BIOMD0000000551 | BioModels
2005-01-01 | MODEL1201140005 | BioModels
2005-01-01 | MODEL1201140006 | BioModels
2007-10-10 | E-GEOD-1555 | ArrayExpress
2014-07-30 | BIOMD0000000533 | BioModels
2012-05-14 | E-GEOD-35812 | ArrayExpress
2010-09-29 | E-GEOD-18320 | ArrayExpress